Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12690190 | 0.85 | BACE1 (0.38) | SLC6A2SLC6A4SLC6A3GRIN1GRIN2A | |
| SCHEMBL12690286 | 0.81 | HDAC4 (0.39) | — | |
| SCHEMBL12690183 | 0.79 | BACE1 (0.32) | NISCH | |
| SCHEMBL8020406 | 0.74 | — | — | |
| SCHEMBL7927023 | 0.66 | BACE1 (0.33) | — | |
| SCHEMBL3302614 | 0.66 | BACE1 (0.43) | — | |
| SCHEMBL12693424 | 0.63 | BACE1 (0.40) | — | |
| SCHEMBL12690195 | 0.63 | GLA (0.37) | SLC6A2SLC6A4SLC6A3GLANISCH | |
| SCHEMBL6877967 | 0.63 | BACE1 (0.35) | — | |
| SCHEMBL932759 | 0.63 | BACE1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245155-A1 | FUSED HETEROCYCLIC COMPOUND HAVING AMINO GROUP | SHIONOGI & CO., LTD. (JP) | 2012-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245155-A1 | FUSED HETEROCYCLIC COMPOUND HAVING AMINO GROUP | APP, IAPP, BACE1 | SLC6A2 849/4885SLC6A4 1079/4885SLC6A3 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.